Esra Arisu Naghavi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Esra Arisu Naghavi has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Bakiye Goker Bagca
Department of Medical Biology, Faculty of Medicine, Ege University, Izmir, Turkey
1 shared publication - Burak Gökçe
Faculty of Science, Department of Biology, Ege University, Bornova, İzmir, Türkiye
1 shared publication - Canberk Tomruk
Faculty of Medicine, Department of Histology and Embryology, İzmir Katip Çelebi University , 35620, Çiğli, İzmir
1 shared publication - Cigir Biray Avci
Department of Medical Biology, Faculty of Medicine, Ege University, Izmir, Turkey
1 shared publication - Cumhur Gunduz
Ege University Medical Faculty
1 shared publication - Gurkan Yigitturk
Department of Histology and Embryology, Faculty of Medicine, Muğla Sıtkı Koçman University, Muğla, Türkiye
1 shared publication
Latest Publications
- Open Access
- 30 September 2022
- Published by Medical Journal of Suleyman Demirel University in SDÜ Tıp Fakültesi Dergisi
- Vol. 29 (3) , 324-334
INVESTIGATION OF URSODEOXYCHOLIC ACID EFFECTS ON SIROLIMUS TREATED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS
Objective The usage of mesenchymal stem cells (MSC) with immunosuppressive drugs after organ transplantation is becoming remarkable in clinical applications. However, the drugs negatively affect MSCs. Ursodeoxycholic acid (UDCA), which is an antioxidant molecule, may reverse these effects. The study aims that to determine the effects of sirolimus and UDCA on human adipose tissue-derived MSCs (ADMSCs) individually and in combination. Material and Method The cytotoxicity of the agents was evaluated by WST-1 test in time and dose-dependent manner. The combinational effects were determined using isobologram analysis. Muse cell analyzer was used for the evaluation of apoptosis and cell cycle. Oxidative stress markers were measured by biochemical methods. Results IC50 dose of sirolimus was determined as 18.58μM in the 48th hour. Because no cytotoxic effect was observed at the studied doses of UDCA, the apoptosis, cell cycle, and oxidative stress indicator analyses were continued with a safe dose of 100 μM. Sirolimus promoted apoptosis and inhibited cell proliferation. It was determined that UDCA reduced the apoptotic and anti-proliferative effects of sirolimus on ADMSCs with its anti-oxidant property. Conclusion The UDCA treatment in combination with immunosuppressive therapy after organ and tissue transplantation may have positive effects on ADMSCs.
- 30 September 2022
- Published by Medical Journal of Suleyman Demirel University in SDÜ Tıp Fakültesi Dergisi
- Vol. 29 (3) , 324-334
Open AccessINVESTIGATION OF URSODEOXYCHOLIC ACID EFFECTS ON SIROLIMUS TREATED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS
Objective The usage of mesenchymal stem cells (MSC) with immunosuppressive drugs after organ transplantation is becoming remarkable in clinical applications. However, the drugs negatively affect MSCs. Ursodeoxycholic acid (UDCA), which is an antioxidant molecule, may reverse these effects. The study aims that to determine the effects of sirolimus and UDCA on human adipose tissue-derived MSCs (ADMSCs) individually and in combination. Material and Method The cytotoxicity of the agents was evaluated by WST-1 test in time and dose-dependent manner. The combinational effects were determined using isobologram analysis. Muse cell analyzer was used for the evaluation of apoptosis and cell cycle. Oxidative stress markers were measured by biochemical methods. Results IC50 dose of sirolimus was determined as 18.58μM in the 48th hour. Because no cytotoxic effect was observed at the studied doses of UDCA, the apoptosis, cell cycle, and oxidative stress indicator analyses were continued with a safe dose of 100 μM. Sirolimus promoted apoptosis and inhibited cell proliferation. It was determined that UDCA reduced the apoptotic and anti-proliferative effects of sirolimus on ADMSCs with its anti-oxidant property. Conclusion The UDCA treatment in combination with immunosuppressive therapy after organ and tissue transplantation may have positive effects on ADMSCs.